Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of CBA-1205
jRCT2080225288Phase 1Recruiting
- Sponsor
- Chiome Bioscience Inc.
- Start
- Jul 2020
- Modality
- Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cba-1205 in Non-hematologic malignancy, sponsored by Chiome Bioscience Inc. Primary endpoint: Primary safety and tolerability endpoints. Started Jul 2020; status: recruiting.
02
Drugs
cba-1205
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080225288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225288.